Published in Cancer Res on November 01, 1996
Crystal structures of HINT demonstrate that histidine triad proteins are GalT-related nucleotide-binding proteins. Nat Struct Biol (1997) 1.96
Epigenetic regulation of protein tyrosine phosphatases: potential molecular targets for cancer therapy. Cancer Gene Ther (2005) 1.34
Purification and crystallization of complexes modeling the active state of the fragile histidine triad protein. Protein Eng (1997) 1.07
Identification of PTPN23 as a novel regulator of cell invasion in mammary epithelial cells from a loss-of-function screen of the 'PTP-ome'. Genes Dev (2011) 1.06
Role of protein tyrosine phosphatases in cancer. Prog Nucleic Acid Res Mol Biol (2006) 0.92
Fragile histidine triad protein: structure, function, and its association with tumorogenesis. J Cancer Res Clin Oncol (2009) 0.85
Aberrant transcripts of the FHIT gene are expressed in normal and leukaemic haemopoietic cells. Br J Cancer (1998) 0.80
MiR-19b suppresses PTPRG to promote breast tumorigenesis. Oncotarget (2016) 0.79
Identification of protein tyrosine phosphatase receptor gamma extracellular domain (sPTPRG) as a natural soluble protein in plasma. PLoS One (2015) 0.76
Gene-expression profiles in hereditary breast cancer. N Engl J Med (2001) 29.80
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet (2003) 18.67
A breakpoint map of recurrent chromosomal rearrangements in human neoplasia. Nat Genet (1997) 12.94
Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature (1993) 5.69
The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet (1996) 4.59
TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes Cancer (1995) 4.59
The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer (2008) 3.87
The incidence of fractures of the clavicle. Clin Orthop Relat Res (1994) 3.22
HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet (2002) 3.07
Cytogenetic evidence of clonality in cutaneous benign fibrous histiocytomas: a report of the CHAMP study group. Histopathology (2000) 3.05
The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. Oncogene (2001) 2.97
Telomere dysfunction triggers extensive DNA fragmentation and evolution of complex chromosome abnormalities in human malignant tumors. Proc Natl Acad Sci U S A (2001) 2.91
Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer. J Natl Cancer Inst (2001) 2.74
Recurrent t(16;17)(q22;p13) in aneurysmal bone cysts. Genes Chromosomes Cancer (1999) 2.72
Chromosomal breakage-fusion-bridge events cause genetic intratumor heterogeneity. Proc Natl Acad Sci U S A (2000) 2.61
Host-Symbiont Interactions : V. THE STRUCTURE OF ACIDIC EXTRACELLULAR POLYSACCHARIDES SECRETED BY RHIZOBIUM LEGUMINOSARUM AND RHIZOBIUM TRIFOLII. Plant Physiol (1981) 2.59
DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet (2001) 2.50
High-resolution genome-wide array-based comparative genome hybridization reveals cryptic chromosome changes in AML and MDS cases with trisomy 8 as the sole cytogenetic aberration. Leukemia (2006) 2.45
Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin Cancer Res (2000) 2.43
High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients. Cancer Res (1996) 2.43
Correlation between clinicopathological features and karyotype in lipomatous tumors. A report of 178 cases from the Chromosomes and Morphology (CHAMP) Collaborative Study Group. Am J Pathol (1996) 2.42
Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer. Am J Hum Genet (1997) 2.33
Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol (1998) 2.24
Indicators of prognosis in node-negative breast cancer. N Engl J Med (1990) 2.23
The immunoregulatory mediator macrophage migration inhibitory factor (MIF) catalyzes a tautomerization reaction. Mol Med (1996) 2.21
Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families. Hum Mol Genet (2001) 2.19
Molecular characterization of nocardioform actinomycetes in activated sludge by 16S rRNA analysis. Microbiology (1995) 2.15
Chromosomal imbalance maps of malignant solid tumors: a cytogenetic survey of 3185 neoplasms. Cancer Res (1997) 2.14
Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer (1998) 2.06
Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res (1997) 2.03
Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol (2000) 2.01
Rearrangement of the transcription factor gene CHOP in myxoid liposarcomas with t(12;16)(q13;p11). Genes Chromosomes Cancer (1992) 1.99
Epstein-Barr virus susceptibility of normal human B lymphocyte populations. J Exp Med (1984) 1.94
CD30-positive large cell lymphomas ('Ki-1 lymphoma') are associated with a chromosomal translocation involving 5q35. Br J Haematol (1990) 1.93
Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet (2005) 1.91
Whole-arm t(1;16) and i(1q) as sole anomalies identify gain of 1q as a primary chromosomal abnormality in breast cancer. Genes Chromosomes Cancer (1992) 1.86
A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Res (2000) 1.86
Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer (1997) 1.82
Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer (1999) 1.82
An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res (1997) 1.82
Fusion of the EWS and CHOP genes in myxoid liposarcoma. Oncogene (1996) 1.77
Geographic heterogeneity of neoplasia-associated chromosome aberrations. Genes Chromosomes Cancer (1991) 1.72
Genomic profiling of malignant melanoma using tiling-resolution arrayCGH. Oncogene (2007) 1.72
Classification of BRCA1 missense variants of unknown clinical significance. J Med Genet (2005) 1.71
Cancer risk in humans predicted by increased levels of chromosomal aberrations in lymphocytes: Nordic study group on the health risk of chromosome damage. Cancer Res (1994) 1.70
Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden. Am J Hum Genet (1996) 1.69
The incidence of chronic post-sternotomy pain after cardiac surgery--a prospective study. Acta Anaesthesiol Scand (2001) 1.69
Soluble factor requirements for the autostimulatory growth of B lymphoblasts immortalized by Epstein-Barr virus. J Exp Med (1984) 1.69
Agarose isoelectric focusing of native human immunoglobulin M and alpha 2-macroglobulin. J Immunol Methods (1979) 1.68
Total dietary fiber determined as neutral sugar residues, uronic acid residues, and Klason lignin (the Uppsala method): collaborative study. J AOAC Int (1995) 1.66
Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus. Proc Natl Acad Sci U S A (2000) 1.66
Segregation analysis of balanced pericentric inversions in pedigree data. Clin Genet (1986) 1.65
Isochromosomes in neoplasia. Genes Chromosomes Cancer (1994) 1.64
Structural analysis of complex carbohydrates using high-performance liquid chromatography, gas chromatography, and mass spectrometry. Methods Enzymol (1982) 1.62
Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. Am J Hum Genet (1998) 1.61
A novel and cytogenetically cryptic t(7;21)(p22;q22) in acute myeloid leukemia results in fusion of RUNX1 with the ubiquitin-specific protease gene USP42. Leukemia (2006) 1.60
Expression patterns of the human sarcoma-associated genes FUS and EWS and the genomic structure of FUS. Genomics (1996) 1.59
Trisomy 7 accumulates with age in solid tumors and non-neoplastic synovia. Genes Chromosomes Cancer (2001) 1.53
Cardiac puncture of fetus with Hurler's disease avoiding abortion of unaffected co-twin. Lancet (1978) 1.52
Denaturing high-performance liquid chromatography detects reliably BRCA1 and BRCA2 mutations. Genomics (1999) 1.52
A somatic BRCA2 mutation in RER+ endometrial carcinomas that specifically deletes the amino-terminal transactivation domain. Genes Chromosomes Cancer (1999) 1.49
Characterization of EBV-carrying B-cell populations in healthy seropositive individuals with regard to density, release of transforming virus and spontaneous outgrowth. Int J Cancer (1987) 1.48
Combined morphologic and karyotypic study of 59 atypical lipomatous tumors. Evaluation of their relationship and differential diagnosis with other adipose tissue tumors (a report of the CHAMP Study Group). Am J Surg Pathol (1996) 1.48
Karyotypic characterization of colorectal adenocarcinomas. Genes Chromosomes Cancer (1995) 1.48
Multiple unrelated clonal chromosome abnormalities in an in situ squamous cell carcinoma of the skin. Cancer Genet Cytogenet (1988) 1.48
Occupational exposure to petroleum products in men with acute non-lymphocytic leukaemia. Br Med J (1978) 1.47
Melanoma and nonmelanoma skin cancer in patients with multiple tumours--evidence for new syndromes in a population-based study. Br J Dermatol (2004) 1.46
Clinical significance of cytogenetic findings in solid tumors. Cancer Genet Cytogenet (1997) 1.46
Abnormal nuclear shape in solid tumors reflects mitotic instability. Am J Pathol (2001) 1.44
Amplification and overexpression of p40 subunit of eukaryotic translation initiation factor 3 in breast and prostate cancer. Am J Pathol (1999) 1.42
Trisomy 7 in short-term cultures of colorectal adenocarcinomas. Genes Chromosomes Cancer (1991) 1.41
Incidence of type 1 and type 2 diabetes in adults and children in Kronoberg, Sweden. Diabetes Res Clin Pract (2008) 1.41
Identification of novel candidate genes associated with cleft lip and palate using array comparative genomic hybridisation. J Med Genet (2007) 1.40
Eosinophil granule proteins in cardiopulmonary bypass with and without heparin coating. Ann Thorac Surg (1995) 1.40
Karyotypic comparisons of multiple tumorous and macroscopically normal surrounding tissue samples from patients with breast cancer. Cancer Res (1996) 1.40
Successful treatment of a patient with chronic lymphocytic leukaemia (CLL) presenting with bony metastases with aggressive antibody and chemotherapy. Clin Lab Haematol (2005) 1.39
[Both the hospitals and the primary health care centers are right. The flow of referrals is increasing but not the frequency]. Lakartidningen (1995) 1.39
New chromosomal rearrangement, t(12;22)(p13;q12), in acute nonlymphocytic leukemia. Cancer Genet Cytogenet (1991) 1.39
Abberant cytogenetic evolution pattern of Philadelphia-positive chronic myeloid leukemia treated with interferon-alpha. Leukemia (1996) 1.39
Fluorescence in situ hybridization of old G-banded and mounted chromosome preparations. Cancer Genet Cytogenet (1997) 1.38
BRCA2 germ-line mutations are frequent in male breast cancer patients without a family history of the disease. Cancer Res (1998) 1.37
The natural course of lateral clavicle fracture. 15 (11-21) year follow-up of 110 cases. Acta Orthop Scand (1993) 1.37
The macrophage migration inhibitory factor MIF is a phenylpyruvate tautomerase. FEBS Lett (1997) 1.36